Usted buscó: basofile (Danés - Inglés)

basofile strukturer
basophile structures

at konstatere tilstedeværelsen af basofile granulocytter på et objektglas
confirming the presence of the slide of red blood-corpuscles with basophilic stippling

tacrolimus er også vist at hæmme frigørelse af inflammations mediatorer fra hudmastceller og fra basofile og eosinofile leukocyter.
tacrolimus has also been shown to inhibit the release of inflammatory mediators from skin mast cells, basophils and eosinophils.

behandling med omalizumab medførte en markant nedregulering af fcri-receptorer på basofile celler hos atopiske forsøgspersoner.
treatment of atopic subjects with omalizumab resulted in a marked down-regulation of fcri receptors on basophils.

behandling med tysabri blev associeret med forøgelse af cirkulerende lymfocytter, monocytter, eosinofile granulocytter, basofile granulocytter og kerneholdige røde blodlegemer.
tysabri treatment was associated with increases in circulating lymphocytes, monocytes, eosinophils, basophils and nucleated red blood cells.

forøgelse fra baseline for lymfocytter, monocytter, eosinofile granulocytter og basofile granulocytter varierede inden for området fra 35% til 140% for individuelle celletyper.
increases from baseline for lymphocytes, monocytes, eosinophils and basophils ranged from 35% to 140% for individual cell types but mean cell counts remained within normal ranges.

ved kontrollerede kliniske forsøg over 2 år blev tysabri-behandling associeret med stigning i cirkulerende lymfocytter, monocytter, eosinofile granulocytter, basofile granulocytter og kerneholdige røde blodlegemer.
in 2-year controlled clinical trials in ms patients tysabri treatment was associated with increases in circulating lymphocytes, monocytes, eosinophils, basophils and nucleated red blood cells.

disse omfatter hæmning af frigørelsen af proinflammatoriske cytokiner såsom il-4, il-6, il-8 og il-13 fra humane mastceller/basofile, og ligeledes hæmning af ekspressionen af adhæsionsmolekylet p-selectin på endothelceller.
these include inhibiting the release of proinflammatory cytokines such as il-4, il-6, il-8, and il-13 from human mast cells/basophils, as well as inhibition of the expression of the adhesion molecule p-selectin on endothelial cells.